CONSORT flow diagram.
Total of 60 subjects were accessed for eligibility, out of which 44 were excluded and 1 declined to participate. Remaining 15 subjects participated in this phase-1 clinical study. The subjects were recruited in five different cohorts (n = 3) who were administered with increasing doses of the Ad5-yCD/